King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
23:13
The Hungarian government will offer owners of eligible diesel cars 5,000 forints per month until the end of the year
22:57
Peter Magyar announces changes to Hungary’s adoption law for same-sex couples
22:38
Bucharest entered the Book of Records with “The Table That Unites.” Ciucu: “There was a big dining room today, in Constitution Square”
22:14
Anthropic’s CEO calls for slowing AI development, warning that intelligent agents could take control of the internet in the coming months
21:26
Sergey Lavrov responds to Volodymyr Zelensky: “Let him come to Moscow” for a meeting with Vladimir Putin
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
